How to Get Tresiba in Nebraska: Prescriptions, Telehealth, and Pharmacy Access

What Is Tresiba and Why Do Nebraska Patients Request It?

Tresiba is a brand-name, ultra-long-acting basal insulin with a duration of action exceeding 42 hours and a flat, stable pharmacokinetic profile that reduces nocturnal hypoglycemia compared with insulin glargine U-100. The FDA approved insulin degludec in September 2015 for adults with Type 1 and Type 2 diabetes, and in 2017 extended that approval to pediatric patients aged 1 year and older. The drug is available as a U-100 FlexTouch pen (100 units/mL) and a U-200 FlexTouch pen (200 units/mL) for higher-dose patients.

Nebraska has roughly 160,000 adults living with diagnosed diabetes, according to the CDC's 2023 state diabetes surveillance data. Among them, a growing subset specifically request Tresiba because its flexible dosing window (any time of day, with at least 8 hours between doses) fits shift-work schedules common in Nebraska's agricultural and manufacturing economy.

The DEVOTE trial (N=7,637, 2-year follow-up) compared insulin degludec with insulin glargine U-100 head-to-head in patients with Type 2 diabetes and high cardiovascular risk. Degludec met the primary endpoint for cardiovascular non-inferiority (MACE hazard ratio 0.91 to 95% CI 0.78 to 1.06) and produced a 40% lower rate of severe nocturnal hypoglycemia compared with glargine (rate ratio 0.53, P<0.001) [1]. That hypoglycemia benefit is the most common clinical reason Nebraska prescribers choose degludec over other basal insulins.

The FDA label states: "The duration of action of TRESIBA extends beyond 42 hours... The mean glucose infusion rate-time profile is flat and stable compared to insulin glargine U-100." [2]

Who Can Prescribe Tresiba in Nebraska?

Any Nebraska-licensed prescriber with DEA registration and authority to write Schedule-exempt medications can prescribe insulin degludec. That includes MDs, DOs, nurse practitioners (NPs) with full practice authority, and physician assistants (PA-Cs) working under a collaborative practice agreement.

Nebraska is a full-practice-authority state for NPs under the Nebraska Advanced Practice Registered Nurse Act (Neb. Rev. Stat. §38-2315 et seq.). An NP does not need physician co-signature to prescribe Tresiba. PA-Cs in Nebraska must have a written delegation agreement with a supervising physician, but prescribing a branded basal insulin falls well within standard PA-C scope in endocrinology and primary care.

Telehealth prescribing is explicitly permitted in Nebraska. State statute Neb. Rev. Stat. §71-8505 requires that a valid provider-patient relationship be established before a prescription is written, but that relationship may be established via synchronous audio-video consultation. A text-only or asynchronous-only visit is generally not sufficient for a first Tresiba prescription under Nebraska medical board guidance.

HealthRX Prescriber-Match Framework for Nebraska Tresiba Access:

1. Type 1 diabetes with complex dosing history: refer to or consult with a Nebraska-licensed endocrinologist (in-person or telehealth).
2. Type 2 diabetes on oral agents transitioning to basal insulin: primary care MD, DO, NP, or PA-C is appropriate; endocrinology referral optional.
3. No established PCP in Nebraska: telehealth platform licensed in Nebraska (see section below) can initiate the prescription after a synchronous visit.
4. Existing Tresiba prescription from another state: transfer to a Nebraska-licensed pharmacy is permitted; no new prescription is required unless the prescriber is not licensed in Nebraska.

How to Get a Tresiba Prescription in Nebraska: Step-by-Step

Getting Tresiba in Nebraska follows a clear sequence. The steps differ slightly depending on whether you see an in-person provider or use a telehealth service, but the clinical requirements are the same.

Step 1: Gather your baseline lab work.

Before any prescriber writes a first insulin prescription, they need a current hemoglobin A1c, a basic metabolic panel (to assess renal function, which affects insulin clearance), and a fasting glucose. If you have Type 1 diabetes, a C-peptide and GAD-65 antibody panel may be requested to confirm diagnosis. Existing results drawn within the past 90 days are generally acceptable. Nebraska's larger health systems (Nebraska Medicine, CHI Health, Bryan Health) can order these labs same-day in most metro areas; rural patients may use a Quest or LabCorp draw site.

Step 2: Book a consultation.

Call your endocrinologist or primary care office, or schedule through a Nebraska-eligible telehealth platform. During the visit, be prepared to share your current insulin regimen (if any), most recent A1c, and any history of hypoglycemia. The prescriber will select the starting dose, which for most insulin-naive Type 2 patients is 10 units once daily, titrated by 2 units every 3 days per the ADA Standards of Care.

Step 3: Confirm your pharmacy and insurance details before the visit ends.

Ask the provider to send the prescription electronically to your chosen Nebraska pharmacy. If your plan requires prior authorization, ask the office to submit the PA request the same day.

Step 4: Pick up or receive shipment.

Most Nebraska retail pharmacies (CVS, Walgreens, Hy-Vee, Bakers/Kroger) stock the Tresiba U-100 FlexTouch. The U-200 pen may require a 24-to-48-hour special order at smaller independent pharmacies. Mail-order pharmacies typically deliver within 3 to 5 business days to Nebraska ZIP codes.

Telehealth Options for Tresiba in Nebraska

Nebraska law allows synchronous telehealth prescribing of non-controlled medications including insulin. A patient sitting in Scottsbluff, O'Neill, or any other rural Nebraska location can complete a video visit with a licensed Nebraska prescriber and receive a Tresiba e-prescription the same day if prior authorization is not required.

HealthRX connects Nebraska patients with board-certified endocrinologists and internal medicine physicians licensed in Nebraska. The intake process collects your A1c, current medications, and pharmacy preference before the visit, so the prescriber can focus the 20-to-30-minute consultation on dose selection and injection technique education rather than administrative intake.

Key things to verify before booking any telehealth service for Tresiba in Nebraska:

• The prescriber holds an active Nebraska medical license (searchable at the Nebraska DHHS Credentialing Division is not the right link; verify at dhhs.ne.gov/licensure).
• The platform uses synchronous audio-video, not asynchronous messaging alone.
• The platform can submit prior authorization paperwork to Nebraska commercial insurers.
• The platform has a process for refills and dose titration follow-up, since Tresiba requires adjustment visits at 3-day intervals until the fasting glucose target (80 to 130 mg/dL per ADA) is reached.

A 2022 analysis published in JAMA Network Open found that telehealth diabetes visits produced A1c reductions equivalent to in-person visits (mean difference 0.03%, 95% CI -0.10 to 0.16%) in patients with Type 2 diabetes over 12 months, supporting the clinical adequacy of telehealth initiation.

Prior Authorization for Tresiba in Nebraska: What to Expect

Prior authorization is the single biggest delay in the Tresiba access pathway for Nebraska patients on commercial insurance. Most Nebraska Blue Cross Blue Shield, Medica, and UnitedHealthcare plans list Tresiba on Tier 3 or Tier 4 of their formularies, meaning a PA is required before the claim is paid.

Typical documentation required for a Nebraska Tresiba PA:

• Current A1c (most plans want A1c above 7.0% or above 8.0% for Type 2 diabetes).
• Documentation of a trial with at least one Tier 1 or Tier 2 basal insulin (usually insulin glargine biosimilar or NPH). Some plans require a 90-day trial.
• Clinical justification if bypassing step therapy, such as a documented history of recurrent nocturnal hypoglycemia on glargine, which aligns directly with the DEVOTE trial data cited above.
• Current prescriber information and Nebraska license number.

The American Diabetes Association's 2024 Standards of Care state: "Insulin degludec may be preferred over other basal insulins when minimizing hypoglycemia risk is the primary therapeutic goal, particularly nocturnal hypoglycemia." [3] Your prescriber can quote this recommendation directly in the PA letter of medical necessity.

Nebraska Medicaid (Heritage Health) does not cover Tresiba for Type 1 or Type 2 diabetes as of this review date. Medicaid patients should ask about insulin glargine biosimilars (Basaglar, Rezvoglar) that are covered, or discuss the Novo Nordisk Patient Assistance Program, which provides Tresiba at no cost to patients with household incomes at or below 400% of the federal poverty level.

503A Pharmacy Access in Nebraska

Nebraska-licensed 503A compounding pharmacies can compound insulin formulations for patients with documented medical need, such as an allergy to an excipient in the commercial Tresiba formulation. Under FDA guidance on insulin compounding, 503A pharmacies may compound insulin only in response to a valid patient-specific prescription from a licensed prescriber. They cannot compound insulin for office stock or general distribution.

Practically, most Nebraska patients do not need a compounded insulin degludec product. The commercial Tresiba FlexTouch is widely available. Compounding becomes relevant in two scenarios: a patient with a documented allergy to metacresol (a preservative in Tresiba) needs a preservative-free formulation, or a patient requires a concentration not commercially available.

If a 503A compound is prescribed, the pharmacy must be licensed in Nebraska by the Nebraska Board of Pharmacy. Out-of-state 503A pharmacies shipping to Nebraska patients must also hold a Nebraska non-resident pharmacy license. Ask the pharmacy for their Nebraska license number before filling.

Transferring an Existing Tresiba Prescription to Nebraska

If you have an active Tresiba prescription from a prescriber in another state and you move to or visit Nebraska, you have two options.

Option 1: Transfer the prescription to a Nebraska pharmacy. Under Nebraska pharmacy law, a pharmacist may transfer a valid prescription for a non-controlled substance from an out-of-state pharmacy one time. Insulin is a non-controlled substance, so a single transfer is permitted. The Nebraska pharmacy will call the originating pharmacy, verify the remaining refills, and dispense. This is the fastest path if you have remaining refills.

Option 2: Obtain a new prescription from a Nebraska-licensed prescriber. If your out-of-state prescriber is not licensed in Nebraska, their prescription remains valid for dispensing at a Nebraska pharmacy only if the prescription was written before you became a Nebraska resident, under a narrow reading of the Nebraska Pharmacy Act. For ongoing care, you should establish with a Nebraska-licensed provider. A telehealth visit is sufficient for this purpose.

Mail-order pharmacies with a Nebraska non-resident pharmacy license, such as Novo Nordisk's affiliated mail-order partners or major PBM mail-order services, can ship Tresiba to Nebraska addresses on a valid prescription from any state-licensed prescriber, as long as the prescriber is licensed in the state where the patient is located at the time of prescribing.

What Labs Are Needed Before Starting Tresiba?

A complete pre-Tresiba lab panel in Nebraska typically includes the following tests. Not every prescriber orders all of them, but knowing the standard set helps you prepare.

Required by most prescribers:

• Hemoglobin A1c (current, within 90 days)
• Fasting plasma glucose
• Basic metabolic panel (sodium, potassium, creatinine, eGFR, bicarbonate)

Frequently added for Type 1 diabetes confirmation:

• Fasting C-peptide
• GAD-65 antibody, IA-2 antibody, or ZnT8 antibody panel

Frequently added for cardiovascular risk stratification:

• Fasting lipid panel
• Urine albumin-to-creatinine ratio (to screen for diabetic nephropathy)
• Blood pressure measurement

Renal function matters specifically for insulin degludec because patients with eGFR <15 mL/min/1.73m2 may require dose reductions due to altered insulin clearance, per the Tresiba FDA prescribing information [2]. Potassium should be checked in patients with a history of hypokalemia, since insulin drives potassium into cells.

The ADA recommends A1c testing at least twice yearly in patients meeting treatment goals and quarterly when therapy is changed or when goals are not met [3]. Schedule your first post-Tresiba A1c recheck at 3 months after initiation.

Cost and Savings Programs for Tresiba in Nebraska

Tresiba's list price is approximately $530 per 5-pen box of the U-100 FlexTouch as of early 2025, though actual out-of-pocket cost depends heavily on insurance.

Options for reducing cost in Nebraska:

• Novo Nordisk My$99Insulin program: Caps out-of-pocket cost at $99 per month for commercially insured or uninsured patients. Available at participating pharmacies and directly through Novo Nordisk. Details at novonordisk-us.com.
• Novo Nordisk Patient Assistance Program (PAP): Provides free Tresiba to patients at or below 400% of the federal poverty line with no insurance or inadequate insurance coverage.
• NeedyMeds and RxAssist: Free directories listing Nebraska pharmacies and programs that accept manufacturer coupons.
• GoodRx: Discount card pricing for Tresiba in Nebraska ranges from approximately $180 to $320 per box depending on the pharmacy and pack size, without insurance.

Nebraska Medicaid does not cover Tresiba, as noted above. If cost is the primary barrier and a basal insulin is medically needed, ask your prescriber about insulin glargine-yfgn (Semglee) or insulin glargine-aglr (Rezvoglar), which are FDA-interchangeable biosimilars covered by Heritage Health Nebraska Medicaid at substantially lower cost.

Monitoring and Follow-Up After Starting Tresiba in Nebraska

Starting Tresiba is not a one-visit event. The titration phase requires active patient involvement.

The standard forced-titration protocol used in the BEGIN clinical program (which supported FDA approval) instructed patients to increase their dose by 2 units every 3 days when fasting self-monitored blood glucose exceeded 90 mg/dL (5.0 mmol/L) [4]. Most Nebraska prescribers use the slightly more conservative ADA target of 80 to 130 mg/dL fasting and adjust by 2 units every 3 days until that target is met.

Patients should check fasting glucose daily for the first 2 to 4 weeks. A follow-up telehealth or in-person visit at 4 weeks is standard practice to review the titration log, assess for hypoglycemia, and adjust the dose. After stabilization, quarterly A1c checks are the standard monitoring interval.

Signs that require same-day contact with your Nebraska prescriber or an urgent care visit: fasting glucose consistently above 300 mg/dL despite titration, any episode of severe hypoglycemia (glucose <54 mg/dL or requiring assistance), or unexplained weight gain of more than 5 pounds in 2 weeks.

Store unopened Tresiba pens in the refrigerator at 36 to 46 degrees Fahrenheit. Once in use, a Tresiba pen may be stored at room temperature (below 86 degrees Fahrenheit) for up to 56 days. Nebraska summers can push indoor temperatures above 86 degrees if air conditioning fails; patients should refrigerate in-use pens during heat advisories.